^
Association details:
| Biomarker: | PLEKHH2-ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PLEKHH2-ALK: A novel in-frame fusion with durable response to alectinib- utilizing RNA sequencing in search for hidden gene fusions susceptible to targeted therapy.
Published date:
08/10/2020
Excerpt:
PLEKHH2-ALK rearrangement, an in-frame novel fusion, was identified using RNA sequencing. The patient was initiated on alectinib after progressing on four cycles of chemo-immunotherapy in part due to a technical delay in molecular testing. At 18 months, her tumor continues to respond to alectinib.
DOI:
https://doi.org/10.1016/j.cllc.2020.07.017
